JP5791512B2 - 組織因子経路阻害因子（ｔｆｐｉ）に対する抗体 - Google Patents

組織因子経路阻害因子（ｔｆｐｉ）に対する抗体 Download PDF

Info

Publication number
JP5791512B2
JP5791512B2 JP2011541487A JP2011541487A JP5791512B2 JP 5791512 B2 JP5791512 B2 JP 5791512B2 JP 2011541487 A JP2011541487 A JP 2011541487A JP 2011541487 A JP2011541487 A JP 2011541487A JP 5791512 B2 JP5791512 B2 JP 5791512B2
Authority
JP
Japan
Prior art keywords
antibody
tfpi
antibodies
seq
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011541487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012513193A5 (https=
JP2012513193A (ja
Inventor
イーダ・ヒルデン
イェス・トアン・クラウセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2012513193A publication Critical patent/JP2012513193A/ja
Publication of JP2012513193A5 publication Critical patent/JP2012513193A5/ja
Application granted granted Critical
Publication of JP5791512B2 publication Critical patent/JP5791512B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011541487A 2008-12-22 2009-12-18 組織因子経路阻害因子（ｔｆｐｉ）に対する抗体 Expired - Fee Related JP5791512B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08172522 2008-12-22
EP08172522.8 2008-12-22
PCT/EP2009/067566 WO2010072687A1 (en) 2008-12-22 2009-12-18 Antibodies against tissue factor pathway inhibitor (tfpi)

Publications (3)

Publication Number Publication Date
JP2012513193A JP2012513193A (ja) 2012-06-14
JP2012513193A5 JP2012513193A5 (https=) 2012-12-13
JP5791512B2 true JP5791512B2 (ja) 2015-10-07

Family

ID=42104649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011541487A Expired - Fee Related JP5791512B2 (ja) 2008-12-22 2009-12-18 組織因子経路阻害因子（ｔｆｐｉ）に対する抗体

Country Status (6)

Country Link
US (2) US8618263B2 (https=)
EP (1) EP2379599B1 (https=)
JP (1) JP5791512B2 (https=)
CN (1) CN102300876A (https=)
TW (1) TW201026329A (https=)
WO (1) WO2010072687A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379600B2 (en) * 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
JP2013533871A (ja) * 2010-06-30 2013-08-29 ノヴォ ノルディスク アー／エス 組織因子経路インヒビターに特異的に結合することが可能な抗体
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
JP6586016B2 (ja) 2013-03-15 2019-10-02 ノヴォ ノルディスク アー／エス 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
US10457743B2 (en) 2013-07-19 2019-10-29 Novo Nordisk A/S Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
CN106687482B (zh) * 2014-09-17 2022-01-25 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
JP6660957B2 (ja) * 2015-02-25 2020-03-11 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 新規の抗−ｔｆｐｉ抗体及びこれを含む組成物
JP6664467B2 (ja) 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用
BR112021006223A2 (pt) 2018-10-11 2021-07-06 Pfizer regime de dosagem para antagonistas de inibidor da via de fator tecidual (tfpi)
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
WO2025124481A1 (zh) * 2023-12-13 2025-06-19 苏州康宁杰瑞生物科技有限公司 Tfpi抗体用于治疗血友病

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539975A1 (en) * 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
JPH0875736A (ja) * 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法

Also Published As

Publication number Publication date
US20110268745A1 (en) 2011-11-03
JP2012513193A (ja) 2012-06-14
EP2379599A1 (en) 2011-10-26
US20130344090A1 (en) 2013-12-26
TW201026329A (en) 2010-07-16
WO2010072687A1 (en) 2010-07-01
US8618263B2 (en) 2013-12-31
CN102300876A (zh) 2011-12-28
EP2379599B1 (en) 2015-09-02

Similar Documents

Publication Publication Date Title
JP5791512B2 (ja) 組織因子経路阻害因子（ｔｆｐｉ）に対する抗体
RU2562114C2 (ru) Антитела против ингибитора метаболического пути тканевого фактора
JP6025570B2 (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対する最適化されたモノクローナル抗体
JP2015531350A (ja) 末端修飾を有する抗原結合分子
JP2024116399A (ja) 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用
AU2014200227A1 (en) Antibodies against tissue factor pathway inhibitor
CN120152993A (zh) 因子xi催化结构域结合抗体和其使用方法
CN118414168A (zh) 因子xi a2结构域结合抗体和其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140724

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150804

R150 Certificate of patent or registration of utility model

Ref document number: 5791512

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees